|
|
Blood, 1 July 2006, Vol. 108, No. 1, pp. 45-51.
Prepublished online as a Blood First Edition Paper on January 10, 2006; DOI 10.1182/blood-2005-08-3294.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl,
Srdan Verstovsek,
Jorge Cortes,
Farhad Ravandi,
Miloslav Beran,
Guillermo Garcia-Manero,
Alessandra Ferrajoli,
Zeev Estrov,
Susan O'Brien,
Charles Koller,
Francis J. Giles,
William Wierda,
Monica Kwari, and
Hagop M. Kantarjian
From the Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston.
Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities. The overall response (OR) rate was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation. (Blood. 2006;108:45-51)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Prebet, N. Boissel, S. Reutenauer, X. Thomas, J. Delaunay, J.-Y. Cahn, A. Pigneux, B. Quesnel, F. Witz, S. Thepot, et al.
Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup
J. Clin. Oncol.,
October 1, 2009;
27(28):
4747 - 4753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jeha, B. Razzouk, M. Rytting, S. Rheingold, E. Albano, R. Kadota, L. Luchtman-Jones, L. Bomgaars, P. Gaynon, S. Goldman, et al.
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
J. Clin. Oncol.,
September 10, 2009;
27(26):
4392 - 4397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. D. Klepin and L. Balducci
Acute Myelogenous Leukemia in Older Adults
Oncologist,
March 1, 2009;
14(3):
222 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Roboz
Treatment of Elderly Patients with Acute Myeloid Leukemia: Lowering the Intensity
ASCO Educational Book,
January 1, 2009;
2009(1):
378 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Becker, E. Estey, S. Petersdorf, P. C. Hendrie, J. M. Pagel, D. Stirewalt, A. Shustov, B. E. Storer, and F. R. Appelbaum
Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
2964 - 2964.
[Abstract]
|
|
|
|
|
|
|
J. Laubach and A. V. Rao
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Oncologist,
October 1, 2008;
13(10):
1097 - 1108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Berentsen
Rituximab for the treatment of autoimmune cytopenias
Haematologica,
December 1, 2007;
92(12):
1589 - 1596.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Atallah, J. Cortes, S. O'Brien, S. Pierce, M. B. Rios, E. Estey, M. Markman, M. Keating, E. J. Freireich, and H. Kantarjian
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
Blood,
November 15, 2007;
110(10):
3547 - 3551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, R. M. Ricklis, K. Balakrishnan, J. Briel, J. Greer, S. D. Gore, B. D. Smith, M. A. McDevitt, H. Carraway, M. J. Levis, et al.
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
Blood,
September 15, 2007;
110(6):
1762 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Erba
Prognostic Factors in Elderly Patients with AML and the Implications for Treatment
Hematology,
January 1, 2007;
2007(1):
420 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Stock
Controversies in Treatment of AML: Case-based Discussion
Hematology,
January 1, 2006;
2006(1):
185 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
